Last year it took a deal that generated a return multiple of 7x and a 62 percent IRR over a seven-year holding period to win the Buyouts magazine ‘Deal of the Year’ award. (Ovation Pharmaceuticals, bought and sold by GTCR Golder Rauner.) What will it take this year?
That’s a question we’re hoping you’ll help us decide—by voting for your favorite deals in four categories: Small Market Deal of the Year, Middle Market Deal of the Year, Turnaround of the Year and European Deal of the Year. Just follow the links to our online voting booth, where you’ll find brief descriptions of the finalists. The editors of Buyouts will use the results of voting this week to settle on winners in each category; once we have those, we’ll ask you to vote on which of the four winners should also be awarded the coveted ‘Deal of the Year.’ (Please do not vote for your own deals, or ones in which you were involved as a service provider.)
The editors will announce winners in the individual categories via Twitter (@buyouts) in the weeks leading up to our annual Buyouts New York conference April 26-27 at the Waldorf-Astoria Plaza Hotel in New York City. We’ll announce the winner of the ‘Deal of the Year’ during the first-day luncheon on April 26.